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The complete amino acid sequence of helodermin solated from the venom of Gila monster was elucidated. 
The peptide was shown to be a basic pentatriacontapeptide amide: His-Ser-Asp-Ala-Ile-Phe-Thr-Gln-Gln- 
Tyr-Ser-Lys-Leu-Leu-Ala-Lys-Leu-Ala-Leu-Gln-Lys-Tyr-Leu-Ala-Ser-Ile-Leu-Gly-Ser-Arg-Thr-Ser-Pro- 
Pro-Pro-NH,. A high degree of sequence similarities to secretin/VIP/PHI/(PHM)/GRF from mammal and 
bird was observed over the entire N-terminal l-27 sequence. In particular, the amino acid residues in posi- 
tions 3, 6 and 7 were found to be common to 9 peptides of the family. Another interesting feature of the 
structure of helodermin was its C-terminal -Pro-Pro-Pro-NH, sequence. Isolation of helodermin was the 
first demonstration of the existence of a secretin/VIP-related peptide in an animal that is neither mammal 
nor bird. 
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1. INTRODUCTION 
Helodermin has been purified [I] from the 
venom of Gila monster (Heloderma suspecturn). 
The biological and pharmacological activities so 
far demonstrated [1,2] have suggested that the 
newly discovered peptide could be classified in the 
secretin/VIP family of peptides. This paper 
describes the structure elucidation of helodermin. 
2. MATERIALS AND METHODS 
HPLC for purification and identification of 
* To whom correspondence should be addressed 
Abbreviations: VIP, vasoactive intestinal peptide; PHI, 
peptide histidine isoleucine; PHM, peptide histidine 
methionine; GRF, growth hormone-releasing factor; 
HPLC, high-performance liquid chromatography 
natural and synthetic peptides was performed on a 
Toyo-Soda high speed liquid chromatograph 
model SP 8700 and the eluates were monitored 
with a Toyo-Soda Spectrophotometer model 
UV-8-11 at 210 nm wavelength. Amino acid 
analysis was carried out with a Hitachi amino acid 
analyzer model 835 using o-phthalaldehyde. Pro 
and Cys were determined after treatment of the 
column eluates with hypochlorous acid. Peptide 
sequence analysis was performed on an Applied 
Biosystems gas phase protein sequencer model 
470 A. Phenylthiohydantoin (PTH)-amino acids 
liberated in sequence analysis were identified by 
HPLC on a Beckman HPLC instrument consisting 
of a pump system model ‘112, a controller model 
421 and a detector model 165 with a Waters 
automatic sampler model 710 B and a SIC data 
processor model 7000 A. Peptide synthesis was 
carried out by a solid-phase technique [3] with a 
Beckman peptide synthesizer model 990 B. The 
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reagents used included acetonitrile and water for 
HPLC (E. Merck, Darmstadt), bovine trypsin (EC 
3.4.21.4, TPCK-treated) and bovine cr-chymotryp- 
sin (EC 3.4.21.1, TLCK-treated) (Sigma, St Louis, 
MO), and all the reagents needed for sequence 
analysis (Applied Biosystems, Foster City, CA) 
and for peptide synthesis (Protein Research 
Foundation, Osaka). 
2.1. Isolation of helodermin 
Helodermin was isolated from Gila monster 
venom as in [l]. The final purification was per- 
formed by HPLC using a ,uBondapak C- 18 column 
(Waters Assoc., Milford, MA) (3.8 x 300 mm) in 
a 0.01 N HCl/acetonitrile gradient system 
(O/100-20/80, v/v) over 80 min at a flow rate of 
1 .O ml/min. 
2.2. Enzymatic fragmentation 
Purified helodermin (0.4 nmol) was dissolved in 
10% acetic acid (5 pl), to which 1% aqueous am- 
monium bicarbonate (500,ul) and a solution of 
trypsin in 1% aqueous ammonium bicarbonate 
(0.1 pg in 10 ~1) were added. The reaction mixture 
was kept at 25°C for 4 h, then heated in a boiling 
water bath for 5 min and lyophilized. The 
lyophilizate was dissolved in 0.01 N HCl (100~1) 
and the solution was applied to a PBondapak C-l 8 
column (3.8 x 300 cm) for HPLC. The column 
was eluted with a linear gradient system of 0.01 N 
HCl/acetonitrile (O/ 100-40-60, v/v) over 40 min 
at a flow rate of 1.0 ml/min. The fractions con- 
taining peptides were collected and lyophilized, 
then submitted to amino acid analysis and se- 
quence determination. Chymotryptic digestion was 
similarly performed on 1.2 nmol helodermin with 
0.4 fig cy-chymotrypsin. 
2.3. Amino acid analysis 
Each peptide (=50 pmol) was hydrolyzed in 6 N 
HCl (20-50 ~1) containing 4% thioglycollic acid at 
110°C for 24 h in an evacuated tube. The solution 
was evaporated to dryness and the residue was sub- 
mitted to amino acid analysis. 
2.4. Sequence analysis 
The amino acid sequences of a purified prepara- 
tion of helodermin (= 1 .O nmol) and its tryptic and 
chymotryptic fragments (~0.2 nmol each) were 
analyzed according to operation programs 
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OlPREP and RUNTFA provided for the se- 
quencer. In each step of degradation, the reaction 
mixture was applied to an Ultrasphere column 
(Beckman Instruments, Palo Alto, CA) (2 x 
250 mm) heated at 50°C and the column was 
eluted with a gradient solvent system of 
acetonitrile120 mM sodium acetate (pH 4.5) 
(10/90, v/v, for O-l min, 10/90-35/65 for 
l-3 min, 35/65-40/60 for 3-18 min, and 40/60 
for 18-35 min). The eluates were monitored at 
wavelength 269 and 322 nm to identify the PTH- 
amino acids liberated. 
2.5. Peptide synthesis 
Helodermin-related peptides synthesized here 
were H-Leu-Ala-Ser-Ile-Leu-Gly-Ser-Arg-Thr-Ser- 
Pro-Pro-Pro-m and H-Leu-Ala-Ser-Ile-Leu- 
Gly-Ser-Arg-Thr-Ser-Pro-Pro-Pro-m (positions 
23-35). The peptide chain was elongated on a 
chloromethylated polystyrene resin for the peptide 
having a C-terminal free a-carboxylic acid and on 
a benzhydrylamine polystyrene resin for the pep- 
tide having a C-terminal amide, according to a 
program similar to those employed previously 
[4,5]. Protected amino acids used were g-Boc 
derivatives of Pro, Gly, Leu, Ile, Ala, Ser(Bzl), 
Thr(Bz1) and Arg(Tos). When the synthesis of the 
desired peptide was completed, the protected 
peptide-resin was treated with HF in the presence 
of anisole. The resulting peptide was purified by 
gel filtration and reverse-phase HPLC. The purity 
of the synthetic peptides was confirmed by HPLC 
and amino acid analysis of their acid hydrolysates 
and aminopeptidase M digests. Details of the syn- 
thesis and physicochemical characterization of the 
peptides will be presented elsewhere. The two syn- 
thetic tridecapeptides corresponding to helodermin 
(23-35) were used for identification of chymotryp- 
tic fragment C-4 by HPLC on a TSK-GEL- 
ODS-120T column (Toyo Soda, Tokyo) (4.6 x 
250 mm) in a gradient solvent system of 
acetonitrile/30 mM phosphate buffer (pH 7.5) 
(20/80-40/60, v/v) over 20 min at a flow rate of 
1 ml/min. 
3. RESULTS AND DISCUSSION 
Fig.1 shows the final purification profile of 
helodermin on HPLC. The main peak fractions of 
biological activities [1,2] (retention time 41.2 min) 
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were collected and used for structure determina- 
tion. An acid hydrolysate of helodermin contained 
14 different amino acid species in the ratios shown 
in table 1, indicating a pentatriacontapeptide struc- 
ture for the peptide. Sequence analysis with the 
whole molecule of helodermin revealed its N- 
terminal partial structure as being: 
I$s-Ser-Asp-Ala-I~e-Phe-Thr-(Gln)-(Gln)- 
T$-(Ser)-Lys-Leu-Leu-d;a-(Lys)-(Leu)- 
(Ala)-(Leu)-(C%)-(Lys)-?$-(Leu)-----. 
The ambiguous amino acid residues and the C- 
terminal part of the structure were confirmed using 
tryptic and chymotryptic fragments of helodermin. 
HPLC of the tryptic digest yielded 4 major com- 
ponents, T-l to T-4 (fig.2), and the chymotryptic 
digest contained 5 major components, C-l to C-5 
(fig.3). Amino acid compositions of acid 
hydrolysates of the 4 tryptic fragments (table 1) ac- 
counted for 30 of the 35 residues constituting the 
helodermin molecule. Sequence analysis of the 
Fig.1. Final purification of helodermin preparation on 
HPLC (helodermin preparation: 9.6 pg). 
tryptic fragments confirmed the 1-21 sequence of 
helodermin which corresponded to T-l, T-2 and 
T-3. Since the amino acid residues in positions 22 
and 23, i.e., Tyr and Leu, were found to corres- 
pond to the N-terminal two residues of T-4, frag- 
ment T-4 was supposed to be placed next to T-3 
and followed by the 5 amino acid residues, Pro(3), 
Ser(1) and Thr(l), missed in HPLC of the tryptic 
Table 1 
Amino acid compositions of helodermin and its tryptic fragments 
Amino acid Helodermin T-l T-2 T-3 T-4 T-5’ 
Ala 
Arg 
Asx 
GIX 
GlY 
His 
Ile 
Leu 
LYS 
Phe 
Pro 
Ser 
Thr 
Tyr 
Position 
3.98(4) 
1.02(l) 
1.01(l) 
2.87(3) 
1.08(l) 
0.90(l) 
2.16(2) 
5.92(6) 
2.95(3) 
0.97( 1) 
3.19(3)b 
5.05(S) 
1.75(2) 
2.28(2) 
l-35 1-12 13-16 17-21 22-30 31-35 
1.17(l) 
1.11(l) 
2.12(2) 
0.98(l) 
0.97( 1) 
1.14(l) 
1.01(l) 
1.87(2) 
1.04(l) 
1.00(l) 
1.01(l) 0.80(l) 1.22(l) 
1.00(l) 
1.04(l) 
1.78(l) 
0.88( 1) 
1.73(2) 1.38(2) 1.79(2) 
0.99( 1) 0.82( 1) 
(3) 
2.07(2) (1) 
(1) 
0.91(l) 
a Not isolated 
b Determined by using hypochlorous acid 
The values in parentheses represent he theoretical number of residues 
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Fig.2. Elution profile of tryptic digest of helodermin on 
HPLC. 
digest. These results did not conflict with amino 
acid analysis (table 2) and with the sequencing of 
the 5 chymotryptic fragments C-l to C-5. Among 
these fragments, C-4 was assigned to the C- 
terminal fragment of helodermin and shown to 
contain the Thr-Ser-Pro-Pro-Pro sequence at the 
end of its C-terminus. Since the amino acid residue 
in position 30 was found to be Arg, the 5 residues 
which had been missed in HPLC of the tryptic 
digest were inferred to constitute the C-terminal se- 
quence, Thr-Ser-Pro-Pro-Pro, corresponding to 
positions 31-35, which was tentatively designated 
T-5. Although the reason why fragment T-5 was 
not detected by HPLC has not yet been clarified, 
the high hydrophobicity of this fragment might be 
considered as at least partly responsible. 
The question remaining with respect to the 
chemical structure of the C-terminal end group of 
helodermin was answered by a synthetic approach. 
Namely, two tridecapeptides, corresponding to 
fragment C-4 (positions 23-35), were synthesized 
with, respectively, a C-terminal free carboxylic 
acid and the corresponding amide. When com- 
pared with fragment C-4 in terms of retention time 
in HPLC (fig.4), the synthetic tridecapeptide 
amide coeluted with fragment C-4 at a retention 
time of 13.9 min in the system employed and the 
other synthetic peptide showed a different reten- 
tion time (12.0 min). This confirmed the C- 
terminal amide structure of the helodermin 
molecule. Our results, summarized in fig.5, show 
that helodermin is a basic pentatriacontapeptide 
amide. 
Christophe and co-workers have previously 
demonstrated that helodermin interacts with 
secretin or VIP receptors, depending on the system 
tested. The peptide binds to secretin-preferring 
receptors in acini and membranes from rat pan- 
creas [2,6]. It activates adenylate cyclase in rat 
heart through the occupancy of receptors that are 
Table 2 
Amino acid compositions of the chymotryptic fragments of helodermin 
Amino acid C-l c-2 c-3 c-4 c-5 
Ala 
Ar8 
Asx 
Glx 
GlY 
His 
Be 
Leu 
LYS 
Phe 
Pro 
Ser 
Thr 
TYr 
Position 
1.07(l) 
1.06(l) 
1.86(2) 
0.87( 1) 
0.98(l) 
1.08(l) 
0.94(l) 
0.98(l) 
1.62(2) 
0.96(l) 
1.01(l) 
l-13 14-17 18-22 23-35 
1.04(l) 1.05(l) 1.07(l) 
0.91(l) 
0.96(l) 
1.06(l) 
0.97(l) 
2.07(2) 1.02(l) 1.95(2) 
0.96(l) 0.94(l) 
(3) 
3.14(3) 
0.96( 1) 
1.01(l) 
1.68( 1) 
1.01(l) 
1.82(2) 
1.56(l) 
1.44(l) 
0.99( 1) 
0.95(l) 
2.49(2) 
1.34(l) 
1.02( 1) 
2-13 
The values in parentheses represent he theoretical number of residues 
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Fig.3. Elution profile of chymotryptic digest of 
helodermin on HPLC. 
common for secretin and VIP; it recognizes 
specific VIP receptors in rat brain and human 
heart [2]. In addition, 1251-labelled helodermin 
binds to a class of high-affinity VIP receptors in 
rat liver membranes [7]. 
Now, the newly elucidated sequence of heloder- 
min substantiates chemically the close relationship 
of helodermin with secretin/VIP/PHI/GRF 
(fig.6). Located in identical positions to those of 
helodermin are as many as 14-15 amino acid 
residues in porcine, human, and chicken VIP; 
12-13 residues in porcine PHI and human PHI 
(PHM); 10 residues in porcine and chicken 
secretin, and 12 residues in human and rat GRF. In 
particular, the residues in positions 3, 6 and 7 are 
common to all 9 peptides. 
In several precursors of bioactive peptides, the 
formation of a carboxyl terminal a-amide residue 
depends on the sequence X-Gly-basic-basic [S]. 
Helodermin has a C-terminal prolinamide residue 
(like calcitonin and thyroliberin). This residue, 
representing X in the putative precursor, is in the 
last 35 position of an interesting -Pro-Pro-Pro- 
NH2 sequence. Helodermin is longer than secretin, 
VIP, and PHI/PHM, perhaps due to the fact that 
its glycine in position 28 cannot serve as an amino 
donor to leucine in position 27, because a transi- 
tion mutation has provoked the replacement of an 
AGG codon (for the first of a pair of Arg residues) 
by AGC (for serine 29), in the mRNA encoding the 
peptide. 
Helodermin, a secretory peptide from the sub- 
lingual venomous gland of a lizard, is the first 
demonstration of the production of a 
secretin/VIP/PHI/GRF related peptide in an 
animal other than mammal and bird. Despite 
0 
(B) 
Free 
Amide 
0 10 20 
Elution Volume (ml) 
Fig.4. Identification on HPLC of chymotryptic 
fragment C-4 with synthetic peptides. (A). Elution 
profile of chymotryptic fragments C-4 and C-S. (B) 
Elution profile of synthetic tridecapeptides corres- 
ponding to helodermin (23-35) which have cu-carboxylic 
acid (Free) and cy-carboxyamide (Amide) groups, 
respectively. 
strong homology, helodermin, due to its original 
amino acid sequence (fig.6), displays an original 
pattern of biological activities and might well be 
the prototype of a new class of regulatory peptides 
and not the mere ontogenic variant of a well 
known model. The structure of each peptide in the 
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1 5 10 15 20 
His-Ser-Asp-Ala-Ile-Phe-Thr-Gln-Gln-Tyr-Ser-Lys-Leu-Leu-Ala-Lys-Leu-Ala-Leu-Gln- 
l T-l > c-- T-2 - - T-3 - 
f C-l ? + c-2+ - c-3- 
< c-5 > 
21 25 30 35 
Lys-Tyr-Leu-Ala-Ser-Ile-Leu-Gly-Ser-Arg-Thr-Ser-Pro-Pro-Pro-NH2 
+< T-4-----------, +----(T-5)-----_ 
c-4 > 
Fig.5. The complete amino acid sequence of helodermin. T-l to T-5 represent he tryptic fragments and C-l to C-4 the 
chymotryptic fragments. 
secretin/VIP/PHI/GRF family is, indeed, quite 
conservative throughout evolution. This hypo- 
thesis is now being actively tested in our labora- 
tories. 
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THE VIP-SECRETIN-PHI FAMILY OF PEPTIDES. 
SPECIES PEPTIDE 1 5 10 15 20 25 30 35 40 45 
9 
p/h 
c 
P 
h 
P 
c 
h 
!J 
HELOOERHIN : 
VIP : 
VIP : 
PHI : 
PHM : 
SECRETIN : 
SECRETIN : 
CRF (l-44) : 
GRF (l-43) : 
H-S~-A-I~-T-Q-Q-Y-S-K~~-A-K-L-A~~~-Y~-A-S-I~-G-S-R-T-S-P-P-P-* ------- ----- ___ _-_ ___ 
H-~~-~-V-F_L-D-N-II-T-R-L-R-K-Q-M-A-V-K-~-~~-N-~-~~-N-* 
H-SD-A-V-F-T-D-N-Y-S-R-F-R-K-Q-M-~-V-K-K-Y~-N-~-V-~-T-* ---- -- -- --- 
H-A-D-G-V-F_L-~-D-F-S_R-L-L-G-Q-~-~-A-K-K-Y~-E-~-L-I -- --- 
H-A-D-G-V-~-~-S-D-F-S~_~~-G-Q-L-S-A-K-~-~~-E-S-L-M 
9 
1 5 10 15 20 25 30 35 40 45 
* : NH2 
SPECIES : b: bovine; c : chlcken; g : Gila monster; h : human; P : porcine; P : rat; 
Fig. 6. Comparison of the amino acid sequence of helodermin with those of VIP, PHI, PHM, secretin and GRF. 
Identities are represented by bold letters and bars. * = a-carboxyamide group. 
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